Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - Spanish Language: Video #21 Treating stage IIIA N2 NSCLC
Author
Luis Raez, MD FACP FCCP
 

Tratamiento para el cáncer de pulmón de células pequeñas en estadio IIIA N2

Para estadios III de cancer de pulmón, el tratamiento es más complicado, porque se trata de una multimodalidad. Idealmente en unos pacientes con estadio III, tienen que ir a una reunión multidisciplinaria donde tengamos al cirujano, al radiooncólogo y al oncólogo médico porque muchas veces los pacientes en estadio III pueden ir a cirugía y después de la cirugía se les da quimioterapia y radiación (cuando hay compromiso mediastinal o estadio N2), sino a los pacientes en estadio III solo le damos quimioterapia adyuvante después de la cirugía.

El estadio III es complicado porque a veces el paciente no puede ser operado o no estamos seguros de que pueda ser operado. A veces, hay que disminuir el tamaño del tumor por lo que se da quimioterapia primero para reducir el tamaño y ya después se va a cirugía.

Hay varias combinaciones, a veces la tercera opción es que el paciente va a cirugía porque parece operable, pero después de la cirugía descubrimos que hay enfermedad mediastinal (ganglios comprometidos), entonces no solo se le da quimioterapia después de la cirugía, pero también se le tener que dar radiación.

Esas son las tres posibilidades que hay para un estadio III, por eso lo mejor es hacer una reunión multidisciplinaria para decidir en grupo qué es lo mejor para el cancer de pulmón en este estadio.


Treatment for small cell lung cancer in IIIA N2 stage

For lung cancer in stage III, the treatment is more complicated because it is multimodality. Ideally stage III patients should go to a multidisciplinary reunion with a surgeon, radio-oncologist and the oncologist, because sometimes these patients go into surgery and then receive chemotherapy and radiation (only when the mediastinum is affected or is in N2 stage), when they could only receive adjuvant chemotherapy after surgery.

Stage III is complicated because sometimes the patient cannot go into surgery or we are not sure if he is a candidate. Sometimes, we have to reduce the size of the tumor by giving chemotherapy first and then go into surgery. 

There are several combinations, sometimes the third option is the patient going into surgery, but after the procedure we sometimes identify mediastinum affection (lymph nodes are affected), so the treatment has to be of chemotherapy and radiation.

The three options for stage III treatment are available, but it is better to make a multidisciplinary reunion to decide which is the best treatment for the patient.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on